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CLINICAL AND ECONOMIC OUTCOMES OF INVASIVE ASPERGILLOSIS 
(IA) IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
NON-TRADITIONAL HOST: A HOSPITAL DATABASE ANALYSIS
Patel DA1, Gao X2, Stephens JM2, Forshag MS3, Tarallo M3
1Virginia Commonwealth University, Medical College of Virginia, Richmond, VA and 
Pharmerit North America LLC, Bethesda, MD, USA, 2Pharmerit North America LLC, 
Bethesda, MD, USA, 3Pﬁzer Inc, New York, NY, USA
OBJECTIVES: To describe the clinical and economic burden of COPD patients with 
IA (COPD + IA), antifungal treatment patterns, and the impact of index antifungal 
selection on total costs, length of stay (LOS) and mortality. METHODS: This retro-
spective cohort study used 2005–2008 data from the Premier Perspective database of 
>500 U.S. hospitals. COPD + IA patients were identiﬁed based on ICD-9 codes for 
COPD + Aspergillosis + Pneumonia. Patients were excluded if ICD-9 codes were 
present for malignancies, HIV, or conditions that increase risk for IA aside from 
COPD. Demographics, hospital characteristics, and antifungal treatment patterns 
were examined. Excess resource utilization was analyzed by matching cases (COPD + 
IA) and controls (COPD patients without Aspergillosis) on demographic and clinical 
variables. Regression analyses were conducted on the impact of the index antifungal 
on total costs, LOS and mortality controlling for patient demographics, hospital 
characteristics, co-morbidities, and disease severity. RESULTS: We identiﬁed 475 
COPD + IA patients (mean age 69 years, 50% male, 76% Caucasian). COPD + IA 
cases had signiﬁcantly higher costs ($48,163 vs $30,210), LOS (23.2 vs 13.6 days), 
ICU stay (13.8 vs 7.2 days), and mortality (29% vs 23%) compared to COPD controls 
(all p < 0.01). Antifungal therapy was initiated on day 6, with length of therapy of 
15 days, and one-third of patients were in ICU when initiated. Most commonly used 
antifungals were voriconazole, ﬂuconazole, and caspofungin. After controlling for 
covariates, patients receiving ﬂuconazole as the index antifungal had greater mortality 
(40% vs 22%, p = 0.023), 4 additional hospital days (p = 0.007), and 24% greater 
costs (p = 0.003) compared to patients receiving voriconazole ﬁrst-line. Findings were 
consistent in sub-analyses (eg, ICU patients). CONCLUSIONS: COPD + IA patients 
had signiﬁcantly higher mortality, resource utilization, and costs versus controls. 
Treatment with an agent active against Aspergillus increased survival and reduced 
economic burden, thus this potential etiology should be considered when contemplat-
ing antifungal therapy in COPD patients.
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OBJECTIVES: Estimate the incremental impact of HCV on health care costs and 
events using claims data from a large U.S. health insurance provider. METHODS: 1:1 
matched samples of newly diagnosed HCV and non-HCV patients were identiﬁed 
using propensity scoring techniques. Costs and events were measured over the ﬁrst 
post-diagnosis year for HCV patients. Non-HCV patients were assigned an index date 
corresponding to the index date of their matched HCV patient. RESULTS: A total of 
60,806 HCV patients were identiﬁed using 6 years of data based on two or more HCV 
diagnoses or a single diagnosis combined with an HCV-related prescription. Further 
screening for at least one year of eligibility prior to index date and pre-existing HIV, 
hepatitis B, cirrhosis, liver cancer or a liver transplant resulted in an initial HCV 
population of 9191 patients. An additional 410,605 non-HCV patients were identiﬁed 
with similar criteria during their ﬁrst year of eligibility. Both samples were used to 
estimate a parsimonious logistic propensity score model of HCV diagnosis. A total of 
9,129 HCV patients were matched with non-HCV patients [99.3% match rate]. The 
incremental cost of HCV was estimated at +$17,307 over the ﬁrst post-index year. 
HCV doubled the likelihood of hospitalization or a future diagnosis of depression and 
dramatically increased the risk of cirrhosis, liver cancer and liver transplantation were 
increased dramatically by an HCV infection [OR = 62.4, 26.4 and 44.4 respectively]. 
CONCLUSIONS: The incremental cost of HCV in the ﬁrst post-index year is quite 
high due in part to the increased risk of cirrhosis, liver cancer and transplantation. A 
longer term study is needed to investigate economic consequences over time for these 
newly recognized HCV patients.
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THE COST OF TUBERCULOSIS CONTROL IN THE ADULT 
POPULATION OF THE REPUBLIC OF ARMENIA, 2006
Breitscheidel L, Stamenitis S, Bosch C
Kendle GmbH, Munich, Germany
OBJECTIVES: The economic burden of tuberculosis (TB) in Armenia, to our knowl-
edge, has not been assessed. The objective of our study was to estimate total yearly 
direct costs of TB care for adult patients in Armenia, from a societal perspective, for 
2006. METHODS: We used ofﬁcial sources of epidemiological data to estimate the 
total number of prevalent cases of TB within the adult population, including those from 
the civil population and the Armenian penitentiary system. The average direct total 
costs per TB patient were assumed to be similar to the costs reported for the Russian 
Federation. We base this assumption on the similar health care systems, TB policies and 
case management within these two countries. Sensitivity analyses have been conducted 
to deﬁne possible ranges for costs of TB care in Armenia. RESULTS: The incidence and 
prevalence rates of TB in Armenia in 2006 were 48.6 and 176.1 per 100.000 inhabit-
ants, respectively. About 75.9% of all TB cases were smear-positive (BK+); overall 
proportion of children and adolescents was about 8.1%. Assuming that the average 
yearly per-patient costs of managing BK+ and smear-negative (BK-) cases were $359 
and $239, respectively, an overall cost estimate for TB control in the adult population 
of Armenia for 2006 totals to USD 1.41 mill. (range: USD 1.34–1.48 mill.). CONCLU-
SIONS: Despite the uncertainties around current prevalence estimates and cost data per 
TB patient in Armenia, even the lowest possible range of the estimated overall economic 
burden of TB seems to be prohibitively high for a developing country such as Armenia. 
Insufﬁcient ﬁnancial resources available for controlling this disease may contribute to 
the worsening of epidemics. Further studies are warranted to assess the current epide-
miological situation and costs of TB management in Armenia.
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OBJECTIVES: To analyze and compare costs of treatment of complicated infections 
from patients in public and private hospitals METHODS: A retrospective (2008–
2009) medical chart analysis was performed in two hospitals in Sao Paulo City, Brazil: 
Private setting and Public setting. Data from patients over 18 years old with compli-
cated skin/soft tissues infections, complicated abdominal infections and Community 
Acquired Pneumonia (CAP) were analysed according with type and etiologic agent of 
infection, antibiotic use as empiric therapy, bacterial resistance environment and ward 
or ICU treatment and patients. Total treatment costs were evaluated and expressed in 
Brazilian local currency (Reais) RESULTS: A total of 50 medical records randomly 
screened were analyzed, 25 from each hospital. Approximately 34% of each pathology 
and 32% of patients had ICU hospitalization in both settings. The average cost of 
private hospital was R$17,072.08, being 55% due to antibiotics use. Ceftriaxone was 
the most used antibiotic as initial therapy,50% of cases. 56% of patients in private 
hospital had to change antibiotic therapy once at least. In public hospital average cost 
was R$ 2,051.40 and the antibiotics change remained in the same proportion compar-
ing to the private hospital. Mortality rate was different in Private in Public setting 
CONCLUSIONS: The use of appropriate empirical therapy of antibiotic is essential 
and appears as an important cost driver, mainly to the decision makers who under 
these total acknowledgement (scientiﬁc and economic aspects) could have a useful tool 
for supply policy interventions. Furthermore combining clinical and cost allows for 
the best choice of antibiotic use as empirical therapy in these patients
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OBJECTIVES: Acute otitis media (AOM) is extremely common in young children, 
with 75% having at least one episode by one year of age. Streptococcus pneumoniae 
(Sp) and non-typeable Haemophilus inﬂuenzae (NTHi) are the two most commonly 
isolated pathogens in AOM cases. The 7-valent (PCV-7) and 13-valent (PCV-13) 
pneumococcal conjugate vaccines have similar carrier proteins and protect only 
against AOM caused by Sp serotypes contained in the vaccines. The 10-valent pneu-
mococcal vaccine (PHiD-CV) has eight of its ten serotypes conjugated to protein D 
from NTHi and may be regarded as the ﬁrst dual pneumococcal pathogen vaccine 
with a potential to prevent AOM caused by both Sp and NTHi. We estimate the 
clinical and economic impact of these three vaccines on AOM outcomes in Canada. 
METHODS: A steady-state, population-based model with a one-year time horizon 
was developed and calibrated with Canadian epidemiologic and demographic data. 
The health care system perspective was considered assuming 100% vaccination cover-
age, no herd protection and a 3 + 1 vaccination schedule. One-way sensitivity analysis 
was preformed to assess the impact of changes in key model assumptions. RESULTS: 
At price parity, the annual AOM-related cost-savings to the Canadian health care 
system due to the implementation of a PHiD-CV vaccination program is estimated at 
$17.1M and $12.3M compared to PCV-7 and PCV-13 respectively. Compared to 
PCV-7, vaccination with PHiD-CV could prevent an additional 171,162 ambulatory 
visits for AOM, 144,632 antibiotic prescriptions for AOM, and 9,827 hospitalizations 
for myringotomy per year. Compared to PCV-13, PHiD-CV could prevent 123,385 
ambulatory visits for AOM, 104,269 antibiotic prescriptions for AOM, and 7,084 
hospitalizations for myringotomy per year. Sensitivity analyses indicate that efﬁcacy 
against AOM have the biggest impact on model results. CONCLUSIONS: Implemen-
tation of a PHiD-CV vaccination program in Canada is projected to substantially 
reduce AOM burden compared to PCV-7 or PCV-13.
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OBJECTIVES: Determine the cost-effectiveness of three carbapenemic anti-infectives 
(imipenem, meropenem and doripenem) for treatment of VAP in Colombia. 
Abstracts A189
METHODS: A decision analysis model was built based on efﬁcacy measures obtained 
from published clinical trials. Local direct costs were estimated from a payer perspec-
tive using 2009 listed rates of drugs, general ward daily stay and intensive care daily 
stay (with and without mechanical ventilation). The used exchange rate was Col$1968 
per US$ (January 2010). The time horizon was deﬁned as a “censored discharge” (ﬁrst 
to happen among death, discharge or stay until day 35 after therapy ﬁnishing). Effec-
tiveness was measured in terms of clinical cure rates. A multivariate probabilistic 
sensitivity analysis was done through 1000 Monte Carlo simulations. An additional 
model was run including costs associated to the risk of pseudomona transmission. 
These costs were estimated through a Markov model based on the daily probability 
of transmission from an initial pseudomona-free state to contaminated or infected 
states with sensitive and resistant pseudomona strains. RESULTS: Average VAP direct 
costs were US$ 9,912 for imipenem, US$ 10,196 for meropenem and US$ 9,020 for 
doripenem. Costs differences were mainly related to differences in the ICU stay, 
particularly time on mechanical ventilation (13, 13 and 10 days, respectively). Psudo-
mona transmission-related costs were US$ 333; US$ 332 and US$ 191, respectively. 
Monte Carlo analyses showed that doripenem was more cost-effective than merope-
nem and imipenem in 95% and 91% of samples, respectively. Additionally, doripenem 
was dominant over meropenem and imipenem in 46% and 44% of samples, respec-
tively. CONCLUSIONS: Initial treatment of VAP cases with doripenem is the most 
cost-effective alternative compared to other carbapenems as imipenem and merope-
nem. This advantage is related to its effect diminishing the intensive care unit stay due 
to a reduction in time on mechanical ventilation.
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COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS 
LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF PAEDIATRIC 
PATIENTS WITH SYSTEMIC CANDIDA INFECTIONS
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OBJECTIVES: To evaluate the cost-effectiveness of micafungin versus liposomal 
amphotericin B (L-AMB) for ﬁrst-line treatment of invasive candidiasis and candidae-
mia in paediatric patients in the intensive care unit (ICU) setting. METHODS: The 
economic model, designed to simulate a 2-week disease-management period from the 
perspective of the UK National Health Service, used data from a paediatric sub-study 
of a larger, double-blind, randomised trial of micafungin (2 mg/kg) versus L-AMB 
(3 mg/kg). Clinical outcomes included treatment success rates, mortality, treatment 
duration, dosing, discontinuations, and adverse events (AEs). Medical costs included 
acquisition of study drugs, treating drug-related AEs, and hospital length of stays. 
RESULTS: Overall treatment success rates were similar, 73% (35/48) and 76% 
(38/50) in the micafungin and L-AMB arms, respectively; discontinuation rates owing 
to AEs were lower with micafungin, 4% (2/52) compared to 17% (9/54), for L-AMB. 
Average treatment costs were lower (£19,573) in the micafungin versus L-AMB 
(£22,931) groups; the vast majority of these costs were associated with hospitalisation 
(£18,466 and £22,073, respectively), driven by difference in ICU stay. Sensitivity 
analyses showed the results were robustly consistent over a wide range of variables 
but sensitive to length and cost of stay in a paediatric ICU and probability of survival. 
CONCLUSIONS: Micafungin is a cost-effective treatment option compared to L-AMB 
in the management of invasive candidaemia and candidiasis in paediatric patients
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OBJECTIVES: This study conducted cost-effective analysis of compliance-enhancing 
behavioral interventions for highly active antiretroviral therapy (HAART) patients. 
Behavioral interventions, especially concerning costs and adherence associated with 
observed therapy and use of medication event monitoring systems (MEMS), are cur-
rently poorly covered in the existing literature. METHODS: Cost-effective analysis of 
Project MOTIV8 (R01MH68197) was conducted on 204 HIV+ patients in Kansas 
City from 2004 to 2008. The study randomized patients into one of three arms: 
control, enhanced counseling (EC), and EC plus observed therapy (OT). This study 
identiﬁed and analyzed time, direct and indirect costs associated with conducting 
randomized clinical trials (RCT) of motivational interviewing-based behavioral inter-
ventions to enhance HAART adherence. Adherence cutoff was set at ≥80% compli-
ance to HAART. The quality adjusted life values were adapted from previous 
literature. TreeAge® Pro2009 was used to create decision trees, cost-effectiveness 
models and sensitivity analysis. ICER and net beneﬁt was calculated based upon a 
willingness to pay of $50,000/QALY. RESULTS: The direct cost was $125,799($616/
patient) and training cost was $9,710($48/patient). The total time cost associated with 
the recruitment effort came to $245,626($1,204/patient) and evaluation of question-
naires and all patient/professional interactions for all 204 patients was $243,632($1194/
patient). Motivational interviewing costs for 134 EC patients came to $271,133($2023/
patient) and $148,570($2321/patient) for 64 OT patients. Total cost per patient: 
Control = $3062, EC = $5085, EC + OT = $7406. ICER found that EC and EC/OT 
were dominated. EC was $38/QALE(month) and EC/OT was $56/QALE(month). Net 
beneﬁt analysis showed that 59% of the patients in EC have to be adherent in order 
to be equivalent. CONCLUSIONS: This study helps to ﬁll in knowledge gaps associ-
ated with behavioral interventions on HIV patients, especially concerning costs and 
adherence associated with observed therapy and use of MEMS. This economic analysis 
can serve as a guide for clinicians and policymakers in determining cost-efﬁcient treat-
ment strategies for patients with HIV.
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OBJECTIVES: We evaluated the cost-effectiveness of a policy of universal inﬂuenza 
vaccination across the US population, compared with the current approach of vaccinat-
ing selected age and risk groups. METHODS: We modeled costs and outcomes of 
seasonal inﬂuenza under a policy of universal vaccination compared with current 
policy, taking a societal perspective. The population was stratiﬁed to model age-speciﬁc 
(<5, 5–17, 18–49, 50–64, and 65+ years) vaccination coverage assumptions, vaccine 
efﬁcacy, and risks of inﬂuenza complications. Probability of inﬂuenza-related illness 
(ILI) and complications, associated health care utilization, direct and indirect costs, and 
survival were estimated for each policy. Model inputs were derived from published 
literature and public sources. No herd effects were considered. For a season’s interven-
tion, ILI cases in that year and lifetime costs and QALYs lost were calculated for each 
policy and used to derive incremental cost-effectiveness ratios for the overall US popu-
lation. One-way and probabilistic sensitivity analyses (PSA) were conducted. RESULTS: 
In base-case analysis, current policy led to 63 million ILI cases per year, resulting in loss 
of 857,000 QALYs and costs of $115 billion (both discounted at 3% annually; costs 
in 2008 USD), while universal vaccination resulted in 61 million cases, 826,000 QALYs 
lost, and $112 billion in costs. Universal vaccination dominated current recommenda-
tion, costing $3 billion less and averting 2 million cases, resulting in 31,000 fewer 
QALYs lost. Results were most sensitive to the percentage of unvaccinated adults 
developing ILI and coverage assumptions with universal policy. PSA indicated consid-
erable uncertainty of results, with universal coverage was dominant in 54%, and domi-
nated in 20%, of iterations. CONCLUSIONS: Our results indicate that a 
recommendation in of universal vaccination in the US is likely to result in lower costs 
and improved outcomes compared with current recommendation, and that this likeli-
hood depends on seasonal attack rates and coverage assumptions.
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OBJECTIVES: Community-acquired intra-abdominal infections are serious conditions 
and expensive events. The purpose of this study was to develop an economic model 
in order to evaluate the cost-effectiveness ratios between ertapenem and the patterns 
of antibiotics used routinely in the treatment of community-acquired intra-abdominal 
infections at the Social Security Mexican Institute (IMSS) from the health care payer’s 
perspective. METHODS: A cost-effectiveness analysis was developed using a Bayesian 
decision-tree model. The model simulates costs and effectiveness outcomes in a 4-week 
period. The comparators were: ertapenem(1 g daily); metronidazole (500 mg every 8 h)/
amikacin (1 g every 12 h); metronidazole (500 mg every 8 h)/cefotaxime (1 g every 8 h); 
metronidazole (500 mg every 8 h)/ciproﬂoxacin (500 mg every 12 h); metronidazole 
(500 mg every 8 h)/ceftriaxone (1 g every 12 h). Resource use and cost data were 
obtained from clinical records (n = 53) of patients being treated at second-level hos-
pitals at IMSS. Effectiveness measures were the percentage of clinical success without 
adverse events (AE) at the end of the follow-up period. Effectiveness data and transi-
tion probabilities were taken from international published literature and were adjusted 
according to the antimicrobial susceptibility identiﬁed locally. The model was cali-
brated according to international pharmacoeconomics guidelines. One-way and 
probabilistic sensitivity analyses were performed using Monte Carlo Simulation sec-
ond-order approach. RESULTS: Patients who received ertapenem experienced 74.4% 
of clinical success without AE, followed by metronidazole/amikacin (52.6%) and 
metronidazole/cefotaxime (40.6%). Mean cost per patient was lower for ertapenem 
(US$6,293.98) followed by metronidazole/amikacin (US$6,830.78) and metronida-
zole/cefotaxime (US$8,511.03). Regarding the ICER’s, ertapenem resulted the domi-
nant therapy. Acceptability curves showed ertapenem as the most cost-effective 
therapy achieving values close to 100% independently of IMSS willingness to pay. 
CONCLUSIONS: The results showed that in México, ertapenem was the most cost-
effective antibiotic therapy for community-acquired intra-abdominal infections. These 
results should be taken into account by Mexican decision makers.
